UA RABI-20 Tablets

Product Overview

UA RABI-20 is a proton pump inhibitor (PPI) containing Rabeprazole Sodium 20 mg, designed to effectively reduce gastric acid secretion. It provides rapid relief and long-lasting control of acid-related disorders such as GERD, acid reflux, peptic ulcer disease, and erosive esophagitis.

Composition

• Each enteric-coated tablet contains:
  • Rabeprazole Sodium IP – 20 mg

Pharmacological Class

• Class: Proton Pump Inhibitor (PPI)
• ATC Code: A02BC04

Mechanism of Action

Rabeprazole selectively inhibits the H⁺/K⁺-ATPase enzyme system (the gastric proton pump) in the parietal cells of the stomach.

• Blocks the final step of acid production
• Reduces both basal and stimulated gastric acid secretion
• Promotes healing of acid-related mucosal damage

Clinical Indications

UA RABI-20 is indicated for:

• Gastroesophageal Reflux Disease (GERD)
• Duodenal and Gastric Ulcers
• Zollinger–Ellison Syndrome
• Erosive Esophagitis
• Dyspepsia and Acid Peptic Disorders
• Adjuvant therapy with antibiotics for H. pylori eradication

Onset & Duration of Action

• Onset: Within 1 hour
• Peak effect: 2–4 hours
• Duration: Up to 24 hours of acid suppression

Contraindications

• Hypersensitivity to Rabeprazole or any component of the formulation
• Severe hepatic impairment (use with caution)

Adverse Effects

Generally well tolerated.
Possible mild side effects include:

• Headache, dizziness
• Nausea, diarrhea, abdominal pain
• Flatulence or dry mouth

Precautions

• Evaluate for gastric malignancy before initiating therapy.
• Use with caution in patients with liver disease.
• Prolonged therapy may cause hypomagnesemia or vitamin B12 deficiency.